Clinical Trial Update: PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating a PD-L1 inhibitor in combination with apatinib as first-line maintenance therapy for extensive-stage small cell lung cancer and is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• PD-L1 inhibitor (unspecified)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 2 | Status: RECRUITING